Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 70-75

  Spigel, David R ^a,b   Anthony Greco, F ^a,b   Waterhouse, David M ^c   Shipley, Dianna L ^b   Zubkus, John D ^b   Bury, Martin J ^d   Webb, Charles D ^e   Hart, Lowell L ^f   Gian, Victor G ^b   Infante, Jeffrey R ^a,b   Burris, Howard A ^a,b   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Oncology Hematology Care Inc   (United States)

^d Cancer and Hematology Centers of West Michigan   (United States)

^e Consultants in Blood Disorders and Cancer ^*  (United States)

^f Florida Cancer Specialists   (United States)

Author keywords

Bevacizumab; Carboplatin; Ixabepilone; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IXABEPILONE;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; HEART ARRHYTHMIA; HEMOPTYSIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; EPOTHILONES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84866155376     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.008     Document Type: Article

References (38)

1. Helbekkmo N., Sundstrom S.H., Aasebo U., Fr Brunsvig P., von Plessen C., Hjelde H.H., et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007, 97:283-289.
2. Martoni A., Marino A., Sperandi F., Giaquinta S., Di Fabio F., Melotti B., et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005, 41:81-92.
3. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
4. Scagliotti G.V., De Marinis F., Rinaldi M., Crin x00F, Gridelli C., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2002, 346:92-98.
6. Botrel T.E., Clark O., Clark L., Paladini L., Faleiros E., Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer 2011, 74:89-97.
7. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
8. Niho S., Kunitoh H., Nokihara H., Horai T., Ichinose Y., Hida T., et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012, 76:362-367.
9. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
10. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 2006, 355:2542-2550.
11. Scagliotti G., Novello S., Pawel Jv, Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
12. Sparano J.A., Vrdoljak E., Rixe O., Xu B., Manikhas A., Medina C., et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28:3256-3263.
13. Lee F.Y., Borzilleri R., Fairchild C.R., Kim S.H., Long B.H., Reventos-Suarez C., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429-1437.
14. Fumoleau P., Coudert B., Isambert N., Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007, 18(Suppl 5):v9-v15.
15. Lee F.Y., Borzilleri R., Fairchild C.R., Kamath A., Smykla R., Kramer R., et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008, 63:157-166.
16. Lee J.J., Swain S.M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Sem Oncol 2005, 32:S22-S26.
17. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 2007, 25:3389-3391.
18. De Geest K., Blessing J.A., Morris R.T., Yamada S.D., Monk B.J., Zweizig S.L., et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2010, 28:149-153.
19. Mani S., McDaid H., Hamilton A., Hochster H., Cohen M.B., Khabelle D., et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004, 10:1289-1298.
20. Awada A., Piccart M.J., Jones S.F., Peck R.A., Gil T., Lebwohl D., et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol 2009, 63:417-425.
21. Vansteenkiste J., Lara P.N., Le Chevalier T., Breton J.-L., Bonomi P., Sandler A.B., et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non†small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007, 25:3448-3455.
22. Plummer R., Woll P., Fyfe D., Boddy A.V., Griffin M., Hewitt P., et al. A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:8288-8294.
23. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
24. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
25. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 5(3):457-481.
26. Baselga J., Zambetti M., Llombart-Cussac A., Manikhas G., Kubista E., Steger G.G., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009, 27:526-534.
27. Denduluri N., Lee J.J., Walshe J., Berman A.W., Vatas U., Chow C.K., et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007, 25:63-67.
28. Dizon D.S., Blessing J.A., McMeekin D.S., Sharma S.K., Disilvestro P., Alvarez R.D. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009, 27:3104-3108.
29. Hussain M., Tangen C.M., Lara P.N., Vaishampayan U.N., Petrylak D.P., Colevas A.D., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005, 23:8724-8729.
30. Lee D. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer. Clin Prostate Cancer 2004, 3:80-82.
31. Lee F.Y., Smykla R., Johnston K., Menard K., McGlinchey K., Peterson R.W., et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009, 63:201-212.
32. Low J.A., Wedam S.B., Lee J.J., Berman A.W., Brufsky A., Yang S.X., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005, 23:2726-2734.
33. Record Owner NLM: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
34. Roch x00E, Yelle L., Cognetti F., Mauriac L., Bunnell C., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415-3420.
35. Dumontet C., Jordan M.A., Lee F.F. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009, 8:17-25.
36. Rivera E., Lee J., Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008, 13:1207-1223.
37. Lee F.Y., Covello K.L., Castaneda S., Hawken D.R., Kan D., Lewin A., et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008, 14:8123-8131.
38. Patel J.D., Hensing T.A., Rademaker A., Hart E.M., Blum M.G., Milton D.T., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27:3284-3289.